论文部分内容阅读
开搏通(Captopril 以下简称 CPT)是第一个口服有效的血管紧张素转化酶抑制剂。我们应用 CPT 治疗顽固性心衰(RCHF)30例,取得满意疗效。现报告如下。
Captopril (CPT) is the first orally available angiotensin-converting enzyme inhibitor. We use CPT treatment of refractory heart failure (RCHF) in 30 cases, and achieved satisfactory results. The report is as follows.